You are here

FDA Rebuffs Injectafer for Iron Deficiency Anemia

During a recent inspection, issues in the manufacturing facility were noted by FDA inspectors. This is the same facility that is to be used to manufacture Injectafer for the U.S. market. Luitpold is working with the FDA to resolve the problems.

As part of the NDA submission for Injectafer, Luitpold provided the FDA with safety and efficacy data from two randomized clinical trials. One study compared Injectafer with Venofer (iron sucrose injection, USP) in patients with iron deficiency anemia and chronic kidney disease. The second study compared Injectafer with either oral or IV iron (standard of care therapy) in patients with iron deficiency anemia from various causes.

Injectafer was approved by the U.K. Medicines & Healthcare Products Regulatory Agency in 2007. The product is currently registered for use in 40 countries worldwide.

For more information, visit the Luitpold Web site.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market